Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. reports developments as a commercial messenger RNA medicines and vaccines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines. Its news commonly covers pipeline progress for cystic fibrosis and ornithine transcarbamylase deficiency programs, including LUNAR-CF, ARCT-032, LUNAR-OTC and ARCT-810, as well as updates tied to its LUNAR lipid-mediated delivery and STARR self-amplifying mRNA technologies.
Company updates also address KOSTAIVE COVID-19 vaccine activity, partnered vaccine programs with CSL Seqirus, the ARCALIS manufacturing joint venture in Japan, collaboration revenue, research and development spending, quarterly financial results, investor conference participation, and executive or board changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced it will release its financial results for the quarter ended March 31, 2023, after the market close on May 9, 2023. The Company, focused on mRNA medicines for infectious disease vaccines and rare diseases, will also host a conference call and webcast at 4:30 PM ET on the same day. Established in 2013 and based in San Diego, Arcturus utilizes innovative delivery technologies like LUNAR® and STARR™ mRNA Technology. Its pipeline includes candidates for treating ornithine transcarbamylase deficiency and cystic fibrosis, alongside partners in mRNA vaccine programs for COVID-19 and influenza. For more details, visit www.ArcturusRx.com.
Arcturus Therapeutics Holdings announced significant financial results for Q4 2022, highlighting a revenue surge to $160.3 million, driven by a $200 million payment from CSL collaboration. The company achieved $90 million in development milestones in March 2023, bolstering its cash runway into 2026. ARCT-154 Phase 3 trial for COVID-19 booster is fully enrolled in Japan, with ARCT-810 and ARCT-032 advancing in clinical trials. The company reported a net income of $117.3 million for Q4, compared to a loss the previous year. Cash balance was $391.9 million at year-end, reflecting a robust financial position.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will release its financial results for the fourth quarter and full year ended December 31, 2022, after market close on March 28, 2023. A conference call will follow that day at 4:30 p.m. ET. Additionally, Arcturus will present at the Guggenheim Healthcare Talks: Genomic Medicines & Rare Disease Day on April 3, 2023, at 2:10 p.m. ET. Founded in 2013 and based in San Diego, Arcturus focuses on developing mRNA medicines and vaccines for infectious diseases and rare liver and respiratory diseases. The company employs LUNAR® lipid-mediated delivery and STARR™ mRNA Technology to support its diverse pipeline.